Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Dosing insulin based on inaccurate FreeStyle Libre 3 readings can be dangerous, because even small errors may lead to severe hypoglycemia, rebound hyperglycemia, or diabetic ketoacidosis. Sensor readings can drift falsely low or high during the first 24 hours of wear, during compression on the sensor while sleeping, with rapid glucose swings, dehydration, certain medications, or a failing sensor, which is why a confirmatory fingerstick is advised whenever a reading does not match how you feel or before correcting an unexpected high or low. Symptoms like shakiness, confusion, blurred vision, vomiting, fruity breath, or difficulty staying awake warrant urgent medical attention rather than another dose. There are several important factors, warning signs, and troubleshooting steps to consider, so see below to understand more before making dosing decisions.
If your readings feel off and you are unsure whether your symptoms point to low blood sugar, high blood sugar, or something unrelated, a few minutes of clarity can help you act safely instead of guessing; take a free, instant, online symptom check to see what your symptoms may indicate and what steps to take next, including whether you should contact your care team or seek immediate care.
Last reviewed for medical accuracy: 09/13/2026
Continuous glucose monitors (CGMs) like the Freestyle Libre 3 have transformed diabetes management by offering near real-time blood sugar trends. Yet no device is perfect, and relying on an inaccurate reading to dose insulin can carry serious risks. This guide explains why errors happen, what can go wrong, and how to use your Freestyle Libre 3 safely.
• Measures glucose in the fluid between cells (interstitial fluid), not directly in your bloodstream
• Sends glucose readings every minute to a reader or smartphone app
• Reports a Mean Absolute Relative Difference (MARD) of about 8.7% compared to lab reference values¹
• Includes trend arrows indicating how fast and in which direction glucose is changing
While the MARD rating shows good overall accuracy, individual readings can stray higher or lower, especially when blood sugar moves quickly.
When you dose insulin based on an inaccurate CGM value, there are two broad risks:
• Over-estimating your actual glucose level may prompt you to take more insulin than needed
• Severe hypoglycemia (below 54 mg/dL) can cause:
– Shaking, sweating, dizziness
– Confusion, blurred vision, difficulty speaking
– Seizures, loss of consciousness, or even coma if untreated quickly
• Under-estimating your actual glucose level or ignoring a high CGM reading can delay needed insulin
• Persistent hyperglycemia can lead to:
– Increased thirst, frequent urination, fatigue
– Diabetic ketoacidosis (DKA), a life-threatening emergency with nausea, abdominal pain, rapid breathing
Example 1: You just finished an intense workout and see “60 mg/dL ↓↓” on your Libre 3. You feel fine.
• Action: Test with a fingerstick meter. If blood glucose is below 70 mg/dL, treat with 15 g fast-acting carbs and retest in 15 minutes.
Example 2: Post-meal you see “180 mg/dL ↑↑” but no symptoms. You plan a correction dose.
• Action: Wait 10 minutes to let interstitial levels catch up, confirm with a meter if worried, then correct modestly (e.g., 1–2 units), retesting soon after.
The Freestyle Libre 3 offers clear advantages:
• More data points than fingersticks alone
• Fewer skin punctures and greater convenience
• Trend insights that support proactive diabetes management
But remember: It’s a guide, not a guarantee. Pair your CGM with smart habits to maximize benefits and limit danger.
If you experience severe low blood sugar symptoms (convulsions, unconsciousness) or signs of diabetic ketoacidosis (persistent vomiting, difficulty breathing, confusion), these are medical emergencies. Do not wait—call 911 or your local emergency number.
For less urgent concerns—like unexplained trends or recurring alarms—you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker: https://ubiehealth.com/
• Dosing insulin solely on one Freestyle Libre 3 reading can be risky when that reading is inaccurate.
• Understand sensor limitations: lag time, warm-up, artifacts, environmental factors.
• Always confirm unexpected values, especially before large insulin adjustments.
• Use trend arrows, backup fingersticks, and sound clinical judgment.
• Keep emergency supplies on hand and know when to get urgent help.
Your Freestyle Libre 3 is a powerful ally, but it’s not infallible. Combining its data with fingerstick checks and professional guidance helps you stay safe and in control. Above all, if you ever face life-threatening or serious symptoms, speak to a doctor without delay.
––––
¹ MARD reported in Abbott clinical studies.
² The Journal of Diabetes Science and Technology, “Accuracy of Continuous Glucose Monitoring Devices.”
³ U.S. Food and Drug Administration, Freestyle Libre system labeling.
(References)
* Ajjan RA, Battelino T, Cos X, Del Prato S, Philips JC, Meyer L, Seufert J, Seidu S. Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nat Rev Endocrinol. 2024 Jul;20(7):426-440. doi: 10.1038/s41574-024-00973-1. Epub 2024 Apr 8. PMID: 38589493.
* Schubert-Olesen O, Kröger J, Siegmund T, Thurm U, Halle M. Continuous Glucose Monitoring and Physical Activity. Int J Environ Res Public Health. 2022 Sep 28;19(19). doi: 10.3390/ijerph191912296. Epub 2022 Sep 28. PMID: 36231598; PMCID: PMC9564842.
* Benhalima K, Durnwald C, Sweeting A, Adams D, Addala A, Battelino T, Bergenstal RM, Carlson A, Donovan LE, Reis Franco D, Heverly J, Isaacs D, Khunti K, Kihara AB, Levitt N, Levy CJ, Lewer M, Mathiesen E, Murphy HR, Nishimura R, Polsky S, Ram U, Simmons D, Yamamoto JM, Tabák ÁG, Feig D, Scott EM. Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement. Lancet Diabetes Endocrinol. 2026 Feb;14(2):157-177. doi: 10.1016/S2213-8587(25)00335-3. Epub 2025 Dec 17. PMID: 41421368.
* Rodbard D. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. Diabetes Technol Ther. 2017 Jun;19(S3):S25-S37. doi: 10.1089/dia.2017.0035. PMID: 28585879; PMCID: PMC5467105.
* Lind N, Christensen MB, Hansen DL, Nørgaard K. Comparing Continuous Glucose Monitoring and Blood Glucose Monitoring in Adults With Inadequately Controlled, Insulin-Treated Type 2 Diabetes (Steno2tech Study): A 12-Month, Single-Center, Randomized Controlled Trial. Diabetes Care. 2024 May 1;47(5):881-889. doi: 10.2337/dc23-2194. PMID: 38489032.
* Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D, DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi: 10.1001/jama.2016.19975. PMID: 28118453.
* Spanakis EK, Urrutia A, Galindo RJ, Vellanki P, Migdal AL, Davis G, Fayfman M, Idrees T, Pasquel FJ, Coronado WZ, Albury B, Moreno E, Singh LG, Marcano I, Lizama S, Gothong C, Munir K, Chesney C, Maguire R, Scott WH, Perez-Guzman MC, Cardona S, Peng L, Umpierrez GE. Continuous Glucose Monitoring-Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial. Diabetes Care. 2022 Oct 1;45(10):2369-2375. doi: 10.2337/dc22-0716. PMID: 35984478; PMCID: PMC9643134.
* Dunn TC, Ajjan RA, Bergenstal RM, Xu Y. Is It Time to Move Beyond TIR to TITR? Real-World Data from Over 20,000 Users of Continuous Glucose Monitoring in Patients with Type 1 and Type 2 Diabetes. Diabetes Technol Ther. 2024 Mar;26(3):203-210. doi: 10.1089/dia.2023.0565. PMID: 38444315; PMCID: PMC10877396.
* Huang J, Yeung AM, DuBord AY, Wolpert H, Jacobs PG, Lee WA, Drincic A, Spanakis EK, Sherr JL, Prahalad P, Fleming A, Hsiao VC, Kompala T, Lal RA, Fayfman M, Ginsberg BH, Galindo RJ, Stuhr A, Chase JG, Najafi B, Masharani U, Seley JJ, Klonoff DC. Diabetes Technology Meeting 2022. J Diabetes Sci Technol. 2023 Jul;17(4):1085-1120. doi: 10.1177/19322968221148743. Epub 2023 Jan 26. PMID: 36704821; PMCID: PMC10347991.
* Aronson R, Abitbol A, Bajaj HS, Cheng AYY, Christopoulos S, Harris SB, Jain AB, Goldenberg RM. Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2025 Nov;27(11):6220-6242. doi: 10.1111/dom.70008. Epub 2025 Aug 4. PMID: 40757453; PMCID: PMC12515760.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.